Ihekwaba F N
Department of Surgery, University College Hospital, Ibadan, Nigeria.
Postgrad Med J. 1993 Jul;69(813):562-5. doi: 10.1136/pgmj.69.813.562.
The outcome in 57 male patients with breast cancer has been analysed. Four patients with early disease had simple mastectomy (one case) and radical mastectomy (three cases). All four completed a 12-cycle cyclophosphamide/methotrexate/5-fluorouracil (CMF) course of chemotherapy. Two required orchiectomy after 23 and 38 months, respectively. Two patients were alive at 79 and 63 months. Fifty-three others with advanced disease had simple mastectomy (10 cases), radical mastectomy (38 cases) and no surgery (five cases), but only 33 completed chemotherapy and 11 were submitted to orchiectomy for recurrence after a mean interval of 19 months. Two patients were alive at 63 and 69 months, respectively. The overall survival rate was 7%. It is considered that in addition to late presentation (mean (SEM): 16.4 (2.1)) months and advanced disease (93%), ineffectiveness of the CMF regimen in male patients may have contributed to the poor survival rate in these Nigerian patients.
对57例男性乳腺癌患者的治疗结果进行了分析。4例早期疾病患者接受了单纯乳房切除术(1例)和根治性乳房切除术(3例)。这4例患者均完成了12周期的环磷酰胺/甲氨蝶呤/5-氟尿嘧啶(CMF)化疗疗程。其中2例分别在23个月和38个月后需要进行睾丸切除术。2例患者分别在79个月和63个月时仍存活。另外53例晚期疾病患者接受了单纯乳房切除术(10例)、根治性乳房切除术(38例)且未接受手术(5例),但只有33例完成了化疗,11例在平均19个月的间隔后因复发接受了睾丸切除术。2例患者分别在63个月和69个月时仍存活。总生存率为7%。据认为,除了就诊延迟(平均(标准误):16.4(2.1)个月)和疾病晚期(93%)外,CMF方案对男性患者无效可能也是导致这些尼日利亚患者生存率低的原因。